NLS Pharmaceutics Warrant
NLSPW
NLSPW was delisted on the 30th of October, 2025.
6 hedge funds and large institutions have $28.3K invested in NLS Pharmaceutics Warrant in 2024 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, 2 reducing their positions, and 1 closing their positions.
0.03% more ownership
Funds ownership: 2.55% → 2.58% (+0.03%)
0% more funds holding
Funds holding: 6 → 6 (0)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
25% less capital invested
Capital invested by funds: $37.6K → $28.3K (-$9.31K)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$515 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$295 |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$11 |
| 3 |
CS
Clear Street
New York
|
-$10 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AC
1
Armistice Capital
New York
| $17.3K | – | – | – |
|
|
ACM
2
Altium Capital Management
New York
| $6.9K | – | – | – |
|
3
Hudson Bay Capital Management
Stamford,
Connecticut
| $3.01K | – | – | – |
|
|
4
Citadel Advisors
Miami,
Florida
| $482 | +$515 | +16,008 | New |
|
|
5
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $368 | -$11 | -327 | -3% |
|
|
CS
6
Clear Street
New York
| $285 | -$10 | -306 | -4% |
|
|
7
UBS Group
Zurich,
Switzerland
| – | -$295 | -6,023 | Closed |
|
NLSPW Hedge Fund Activity: Q2 2024 in Review
6 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in NLS Pharmaceutics Warrant (NLSPW) for Q2 2024, worth a combined $28.3K — down 25% from $37.6K a quarter earlier.
Fund positioning in NLSPW was balanced in Q2 2024: 1 fund opened new positions, 1 closed out, 0 added to existing stakes and 2 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $515. The largest seller was UBS Group, exiting entirely with an estimated $295 sold.
- 6 institutional investors held NLS Pharmaceutics Warrant (NLSPW) as of Q2 2024, unchanged from Q1 2024.
- Funds reported $28.3K of NLS Pharmaceutics Warrant stock for Q2 2024, down 25% quarter-over-quarter.
- 1 fund opened new NLS Pharmaceutics Warrant positions in Q2 2024 and 1 closed out, a net change of 0 holders.
- The largest NLS Pharmaceutics Warrant buyer in Q2 2024 was Citadel Advisors, an estimated $515 added.
- The largest NLS Pharmaceutics Warrant seller in Q2 2024 was UBS Group, an estimated $295 sold.
Based on aggregated 13F filings for Q2 2024.